Anyone who survives an acute episode of the rare blood disorder TTP is often left with long-term consequences, especially neurological damage. An international study, with the participation of the Department of Hematology of Bern University Hospital, was now able to verify the effectiveness of a new innovative treatment.
The life-threatening blood disorder thrombotic thrombocytopenic purpura (TTP) is rare (2-3 people out of every million per year) and affects mainly young, otherwise healthy people – women more frequently than men. TTP will lead to death if not treated within a few days.
In healthy individuals, the protein scissor ADAMTS13 cleaves ultra large von Willebrand factor (VWF) multimers. Smaller VWF multimers are less sticky, do not bind platelets spontaneously and thus formation of blood clots in blood vessels is prevented.
In TTP, ADAMTS13 is lacking due to circulating autoantibodies. In the absence of VWF size regulation, platelets are consumed in VWF-platelet clots, that occlude the microcirculation. Blood circulation to end organs is decreased, resulting in heart attack, stroke and kidney failure. Hence TTP is also been refered to as “clumping plague”.
So far, standard treatment of acute episodes of TTP consists of a daily plasma exchange (to remove autoantibodies and replenish ADAMTS13) in combination with immunsuppressive drugs (to inhibit autoantibody formation).
Nevertheless, 10 - 20 percent of patients die during an acute episode. In addition, more than half of the survivors have permanent organ damage and dysfunction, particularly in the form of neurological deficits, and frequently experience relapses.
Rapid control of the disorder with lower rate of relapses
A major international study, with the participation of the Department of Hematology of Bern University Hospital, was published on January 9, 2019, in the New England Journal of Medicine (NEJM). The study was able to confirm the effectiveness of an innovative TTP treatment. The studied anti-VWF nanobody, caplacizumab, was shown to effectively prevent VWF-platelet clumping and thus protect the end organs from further depriviation of blood circulation.
145 TTP patients partcipated in this randomized Phase III study, 72 received the nanobody during the plasma exchange treatment and for 30 days thereafter, 73 received a placebo for the same period of time. In 75 percent of patients who received the study drug, the acute phase of TTP ended after 2.95 days, compared to 4.5 days with the conventional treatment.
Furthermore, the patients required fewer plasma exchange sessions (median 5 vs. 7), and could be discharged earlier. The side-effects were comparable in both study arms, although mild bleeding symptoms occurred more frequently with the new compound (65% compared to 48% with placebo). The study was able to confirm the promising data of the Phase II study, in which the Bern-based Hematology Department had also participated.
Long-term research topic at the Bern University Hospital and Bern University
The Department of Hematology at the Bern University Hospital and Bern University (Hematology Research Group, Department of BioMedical Research) have been researching TTP and ADAMTS13 since the mid-1990s. This resarch was initiated by Prof. em. Dr. phil nat. Miha Furlan and Prof. em. Dr. med. Bernhard Lämmle with the discovery of the von Willebrand factor-cleaving protease (now ADAMTS13), and the observation of its deficiency in TTP, and is currently headed by Prof. Dr. med. Johanna Kremer Hovinga. Since 2010 she has been involved in developing the new treatment approach for TTP, which will be available to all TTP patients in the future.
Prof. Dr. med. Johanna A. Kremer Hovinga Strebel, Senior Consulting Physician, Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Johanna.Kremer@insel.ch
Monika Kugemann | idw - Informationsdienst Wissenschaft
Solving the efficiency of Gram-negative bacteria
22.03.2019 | Harvard University
Bacteria bide their time when antibiotics attack
22.03.2019 | Rice University
DESY and MPSD scientists create high-order harmonics from solids with controlled polarization states, taking advantage of both crystal symmetry and attosecond electronic dynamics. The newly demonstrated technique might find intriguing applications in petahertz electronics and for spectroscopic studies of novel quantum materials.
The nonlinear process of high-order harmonic generation (HHG) in gases is one of the cornerstones of attosecond science (an attosecond is a billionth of a...
Nano- and microtechnology are promising candidates not only for medical applications such as drug delivery but also for the creation of little robots or flexible integrated sensors. Scientists from the Max Planck Institute for Polymer Research (MPI-P) have created magnetic microparticles, with a newly developed method, that could pave the way for building micro-motors or guiding drugs in the human body to a target, like a tumor. The preparation of such structures as well as their remote-control can be regulated using magnetic fields and therefore can find application in an array of domains.
The magnetic properties of a material control how this material responds to the presence of a magnetic field. Iron oxide is the main component of rust but also...
Due to the special arrangement of its molecules, a new coating made of corn starch is able to repair small scratches by itself through heat: The cross-linking via ring-shaped molecules makes the material mobile, so that it compensates for the scratches and these disappear again.
Superficial micro-scratches on the car body or on other high-gloss surfaces are harmless, but annoying. Especially in the luxury segment such surfaces are...
The Potsdam Echelle Polarimetric and Spectroscopic Instrument (PEPSI) at the Large Binocular Telescope (LBT) in Arizona released its first image of the surface magnetic field of another star. In a paper in the European journal Astronomy & Astrophysics, the PEPSI team presents a Zeeman- Doppler-Image of the surface of the magnetically active star II Pegasi.
A special technique allows astronomers to resolve the surfaces of faraway stars. Those are otherwise only seen as point sources, even in the largest telescopes...
Researchers at Chalmers University of Technology and the University of Gothenburg, Sweden, have proposed a way to create a completely new source of radiation. Ultra-intense light pulses consist of the motion of a single wave and can be described as a tsunami of light. The strong wave can be used to study interactions between matter and light in a unique way. Their research is now published in the scientific journal Physical Review Letters.
"This source of radiation lets us look at reality through a new angle - it is like twisting a mirror and discovering something completely different," says...
11.03.2019 | Event News
01.03.2019 | Event News
28.02.2019 | Event News
22.03.2019 | Life Sciences
22.03.2019 | Life Sciences
22.03.2019 | Information Technology